Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 102-111

  Binder, Joseph ^a   Tetangco, Selwyna ^a,b   Weinshank, Megan ^a   Maegley, Karen ^a   Lingardo, Laura ^a   Diehl, Wade ^a   Love, Robert ^a   Patick, Amy K ^a,c   Smith, George J ^a  

^a PFIZER INC   (United States)

^b Life Technologies   (United States)

^c Adamas Pharmaceuticals Inc   (United States)

Author keywords

Chimeric replicon; HCV; NS3 protease

Indexed keywords

CILUPREVIR; PF 3227006; PF 3794190; PF 3953799; PF 968989; PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REPLICON; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; BINDING SITES; CARBAMATES; CELL LINE; CLONING, MOLECULAR; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIATION; GENETIC VECTORS; GENOTYPE; HEPACIVIRUS; HUMANS; MACROCYCLIC COMPOUNDS; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; PHYLOGENY; PROTEASE INHIBITORS; QUINOLINES; REPLICON; SEQUENCE ANALYSIS, PROTEIN; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 79958279971     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.007     Document Type: Article

References (33)

1. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Current Protocols in Molecular Biology 1999, John Wiley and Sons, Inc., Hoboken, New Jersey.
2. Benhamou Y., Moussalli J., Ratziu V., Lebray P., Gysen V., de Backer K., Ghys A., Van Heeswijk R., Vangeneugden T., Picchio G., Beumont-Mauviel M. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J. Hepatol. 2009, 50(Suppl. 1):6.
3. Blight K.J., McKeating J.A., Marcotrigiano J., Rice C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 2003, 77:3181-3190.
4. Blight K.J., Norgard E.A. HCV replicon systems. Hepatitis C viruses: genomes and molecular biology 2006, 311-351. Horizon Bioscience, Norfolk, UK. S.L. Tan (Ed.).
5. Date T., Kato T., Miyamoto M., Zhao Z., Yasui K., Mizokami M., Wakita T. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J. Biol. Chem. 2004, 279:22371-22376.
6. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 2002, 36:S121-S127.
7. Forestier N., Larrey D.G., Guyader D., Marcellin P., Rouzier R., Patat A.A., Bradford W.Z., Porter S., Zeuzem S. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology 2008, 48:1132A.
8. Foster, G.R., Hezode, C., Bronowicki, J.P., Carosi, G., Weiland, O., Verlinden, L., van Heeswijk, R., Van Baelen, B., Picchio, G., Beumont-Mauviel, M., 2010. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of study C209. 45th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria.
9. Hao W., Herlihy K.J., Zhang N.J., Fuhrman S.A., Doan C., Patick A.K., Duggal R. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 2007, 51:95-102.
10. Hao W., Weady P., Maldonado F., Patick A., Duggal R. Discovery of two novel classes of inhibitors of hepatitis C virus (HCV) replication utilizing a dicistronic reporter HCV replicon high throughput assay. Antiviral Res. 2007, 74:A58.
11. Herlihy K.J., Graham J.P., Kumpf R., Patick A.K., Duggal R., Shi S.T. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 2008, 52:3523-3531.
12. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., Forns X., Erhardt A., Cronlein J., Chaves R.L., Yong C.L., Nehmiz G., Steinmann G.G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347-1355.
13. Kato T., Date T., Miyamoto M., Furusaka A., Tokushige K., Mizokami M., Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125:1808-1817.
14. Kato T., Matsumura T., Heller T., Saito S., Sapp R.K., Murthy K., Wakita T., Liang T.J. Production of infectious hepatitis C virus of various genotypes in cell cultures. J. Virol. 2007, 81:4405-4411.
15. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
16. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102:2992-2997.
17. Li X.D., Sun L., Seth R.B., Pineda G., Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 2005, 102:17717-17722.
18. Lin C., Hanzelka B.L., Muh U., Kovari L., Bartels D.J., Tigges A.M., Miller J., Rao B.G., Kwong A.D. Telaprevir (VX-950) is a potent inhibitor of HCV-NS3 proteases derived from genotype non-1 HCV-infected patients, 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) 2007, Barcelona, Spain.
19. Lindenbach, B., Rice, C., 2001. Flaviviridae: the viruses and their replication. Fields Virology, pp. 991-1041.
20. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
21. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
22. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 1992, 66:3225-3229.
23. Pawlotsky J.M. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin. Liver Dis. 2003, 7:45-66.
24. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., de Rooij J., McNair L., Purdy S., Kauffman R., Alam J., Jansen P.L. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
25. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.L., Nehmiz G., Steinmann G.G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005, 41:832-835.
26. Robertson B., Myers G., Howard C., Brettin T., Bukh J., Gaschen B., Gojobori T., Maertens G., Mizokami M., Nainan O., Netesov S., Nishioka K., Shini T., Simmonds P., Smith D., Stuyver L., Weiner A. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 1998, 143:2493-2503.
27. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., Hussain M., Shah A., Cutler D., Zhang J., Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132:1270-1278.
28. Shi S.T., Herlihy K.J., Graham J.P., Nonomiya J., Rahavendran S.V., Skor H., Irvine R., Binford S., Tatlock J., Li H., Gonzalez J., Linton A., Patick A.K., Lewis C. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2009, 53:2544-2552.
29. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 2004, 85:3173-3188.
30. Taliani M., Bianchi E., Narjes F., Fossatelli M., Urbani A., Steinkuhler C., De Francesco R., Pessi A. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal. Biochem. 1996, 240:60-67.
31. Thibeault D., Bousquet C., Gingras R., Lagace L., Maurice R., White P.W., Lamarre D. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 2004, 78:7352-7359.
32. Tong X., Guo Z., Wright-Minogue J., Xia E., Prongay A., Madison V., Qiu P., Venkatraman S., Velazquez F., Njoroge F.G., Malcolm B.A. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 2006, 45:1353-1361.
33. Tripathi R.L., Krishnan P., He Y., Middleton T., Pilot-Matias T., Chen C.M., Lau D.T., Lemon S.M., Mo H., Kati W., Molla A. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res. 2007, 73:40-49.